Table 1.
Herbal Raw Material |
Active Compounds | Functions | Mechanism of Action | Model | Dose | References |
---|---|---|---|---|---|---|
Leaves | Phenolic groups (naringenin and quercetin) | Cardioprotective Antioxidant |
↑ scavenging of free radicals (OH) ↓ peroxidation of lipids ↓ GSH, Gpx, SOD, CAT, TBARS |
male albino Wistar rats | 500 mg/kg b.w. for 15 days p.o. | [9] |
Flavonoids (isoflavones, flavanone, flavonols, morusin, cyclomorusin, and neocyclomorusin) Novel prenylated flavonoids (isoquercetin, quercetin, astragalin, and scopoline) Glycosides (namelyroseoside III and benzyl D–glucopyranoside) |
Antihypertensive Antioxidant Cardioprotective |
↑ cellular antioxidants (↑ GSH, SOD, and CAT, ↓ LPO) ↓ heart rate, ↓ heart weight ↓ pressure-rate index ↓ levels of cardiac damage marker enzymes |
male Wistar rats | 25, 50, 100 mg/kg b.w. for three weeks p.o. | [10] | |
Antihypertensive Hypolipidemic Vascular improvement Lipid regulation agent |
↓ of cell adhesion molecule (E–selectin, VCAM–1, ICAM–1) expression in the aorta | male rats | 100, 200 mg/kg b.w. for 14 weeks | [13] | ||
Rutin, chlorogenic acid, astragalin | Vascular effect | ↑ NO, eNOS ↑ phosphorylation of PERK and HSP90 at threonine |
mice | 100, 200, or 400 mg/kg b.w. | [11] | |
Rutin and isoquercetin | Antiplatelet Antithrombotic Prevention or treatment of myocardial infarction |
↓ MAPK–integrin α IIb β 3 ↓ PLA2/TXA2 routes ↓ TXB2 formation ↓ serotonin secretion ↓ aggregation ↓ thrombus formation |
male Sprague–Dawley rats | 100, 200, 400 mg/kg b.w. for 3 days | [12] | |
Mulberroside A, chlorogenic acid, cryptochlorogenic acid, astragaloside, resveratrol, scopoletin, 1–deoxynojirimycin | Glucose improvement Lipid metabolism improvement |
↓ TGF–β–Smad2/3 | male C57BL/6 mice | 1000 mg/kg b.w. for 12 weeks p.o. | [14] |
↑—increased, ↓—decreased.